Oncolytics Biotech is an immuno-oncology company focused on advancing pelareorep, an intravenously delivered immuno-oncolytic virus, toward regulatory approval in metastatic breast cancer and other indications with high unmet needs. Oncolytics’ diverse clinical pipeline is supported by compelling clinical data demonstrating pelareorep’s safety, efficacy, immunotherapeutic mechanism of action, and potential to increase the proportion of patients responding to immune checkpoint inhibitors.